Seth Ettenberg, PhD, is the President and Chief Executive Officer at BlueRock Therapeutics. Seth joined BlueRock as Chief Scientific Officer in 2020 and led the rapid expansion and advancement of BlueRock’s pipeline. Prior to joining BlueRock, Seth was a founding member of Unum Therapeutics where he served as Chief Scientific Officer. At Unum Seth built and lead the strategy team that supported strategic partnerships, four first in class clinical trials, several rounds of fundraising, and a successful NASDAQ IPO listing. Previously Seth led the Cambridge site of Novartis’ Oncology Biotherapeutics group where he was responsible for developing and leading the strategy and implementation for oncology drug development projects at the Novartis Institutes for Biomedical Research (NIBR). In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T-cell therapeutics. Seth received his formal scientific training at the Genetics Branch of the National Cancer Institute.